Refine
Is part of the Bibliography
- yes (19711) (remove)
Year of publication
Document Type
- Doctoral Thesis (8978)
- Journal article (8635)
- Complete part of issue (703)
- Book article / Book chapter (334)
- Book (197)
- Conference Proceeding (197)
- Preprint (130)
- Review (110)
- Master Thesis (104)
- Report (93)
Language
- English (11169)
- German (8457)
- French (50)
- Multiple languages (21)
- Russian (6)
- Spanish (5)
- Portuguese (2)
- Italian (1)
Keywords
- Würzburg (739)
- Universität (668)
- Wuerzburg (668)
- Wurzburg (660)
- University (608)
- Organische Chemie (135)
- Psychologie (127)
- Anorganische Chemie (124)
- Maus (124)
- Toxikologie (123)
Institute
- Theodor-Boveri-Institut für Biowissenschaften (2327)
- Graduate School of Life Sciences (1042)
- Physikalisches Institut (816)
- Institut für Anorganische Chemie (679)
- Medizinische Klinik und Poliklinik I (669)
- Institut für Psychologie (610)
- Medizinische Klinik und Poliklinik II (589)
- Institut für Organische Chemie (566)
- Neurologische Klinik und Poliklinik (530)
- Klinik und Poliklinik für Allgemein-, Viszeral-, Gefäß- und Kinderchirurgie (Chirurgische Klinik I) (510)
Schriftenreihe
- Cultural Animal Studies, Band 3 (2)
- Spezielle Didaktik der Sportarten (2)
- Alter Orient und Altes Testament : Sonderreihe Veröffentlichungen zur Kultur und Geschichte des Alten Orients ; 3 (1)
- Berichte aus der Informatik (1)
- Deuterocanonical and Cognate Literature Studies (1)
- Deuterocanonical and Cognate Literature Yearbook (1)
- European Journal of Clinical Nutrition ; 70 (1)
- Forum Junge Romanistik 18 (1)
- Grundzüge ; 45 (1)
- International Archives of the History of Ideas / Archives internationales d’histoire des idées 242 (1)
Sonstige beteiligte Institutionen
- Johns Hopkins School of Medicine (18)
- Fraunhofer-Institut für Silicatforschung ISC (8)
- Helmholtz Institute for RNA-based Infection Research (HIRI) (8)
- IZKF Nachwuchsgruppe Geweberegeneration für muskuloskelettale Erkrankungen (7)
- Akademie der Wissenschaften und der Literatur, Mainz (6)
- DFG Forschungsgruppe 2757 / Lokale Selbstregelungen im Kontext schwacher Staatlichkeit in Antike und Moderne (LoSAM) (6)
- Clinical Trial Center (CTC) / Zentrale für Klinische Studien Würzburg (ZKSW) (5)
- Johns Hopkins University School of Medicine (5)
- Universität Leipzig (5)
- Universitätsklinikum Würzburg (5)
ResearcherID
- B-1911-2015 (1)
- B-4606-2017 (1)
- C-2593-2016 (1)
- D-1221-2009 (1)
- D-1250-2010 (1)
- D-3057-2014 (1)
- I-5818-2014 (1)
- J-8841-2015 (1)
- M-1240-2017 (1)
- N-2030-2015 (1)
Millions of people regularly play so-called massively multiplayer online role playing games (MMORPGs). Recently, it has been argued that MMORPG overuse is becoming a significant health problem worldwide. Symptoms such as tolerance, withdrawal, and craving have been described. Based on behavioral, resting state, and task-related neuroimaging data, we test whether frequent players of the MMORPG "World of VVarcraft" (WoW) similar to drug addicts and individuals with an increased risk for addictions show a generally deficient reward system. In frequent players of the MMORPG "World of VVarcraft" (WoW-players) and in a control group of non-gamers we assessed (1) trait sensitivity to reward (SR), (2) BOLD responses during monetary reward processing in the ventral striatum, and (3) ventral-striatal resting-state dynamics. We found a decreased neural activation in the ventral striatum during the anticipation of both small and large monetary rewards. Additionally, we show generally altered neurodynamics in this region independent of any specific task for WoW players (resting state). On the behavioral level, we found differences in trait SR, suggesting that the reward processing deficiencies found in this study are not a consequence of gaming, but predisposed to it. These findings empirically support a direct link between frequent online gaming and the broad field of behavioral and drug addiction research, thus opening new avenues for clinical interventions in addicted gamers and potentially improving the assessment of addiction-risk in the vast population of frequent gamers.
The human intestinal parasite Schistosoma mansoni causes a chronic disease, schistosomiasis or bilharzia. According to the current literature, the parasite induces vigorous immune responses that are controlled by Th2 helper cells at the expense of Th1 helper cells. The latter cell type is, however, indispensable for anti-viral immune responses. Remarkably, there is no reliable literature among 230 million patients worldwide describing defective anti-viral immune responses in the upper respiratory tract, for instance against influenza A virus or against respiratory syncitial virus (RSV). We therefore re-examined the immune response to a human isolate of S. mansoni and challenged mice in the chronic phase of schistosomiasis with influenza A virus, or with pneumonia virus of mice (PVM), a mouse virus to model RSV infections. We found that mice with chronic schistosomiasis had significant, systemic immune responses induced by Th1, Th2, and Th17 helper cells. High serum levels of TNF-alpha, IFN-gamma, IL-5, IL-13, IL-2, IL-17, and GM-CSF were found after mating and oviposition. The lungs of diseased mice showed low-grade inflammation, with goblet cell hyperplasia and excessive mucus secretion, which was alleviated by treatment with an anti-TNF-alpha agent (Etanercept). Mice with chronic schistosomiasis were to a relative, but significant extent protected from a secondary viral respiratory challenge. The protection correlated with the onset of oviposition and TNF-alpha-mediated goblet cell hyperplasia and mucus secretion, suggesting that these mechanisms are involved in enhanced immune protection to respiratory viruses during chronic murine schistosomiasis. Indeed, also in a model of allergic airway inflammation mice were protected from a viral respiratory challenge with PVM.
Despite the completion of the Arabidopsis genome sequence, for only a relatively low percentage of the encoded proteins experimental evidence concerning their function is available. Plant proteins that harbour a single PLAT (Polycystin, Lipoxygenase, Alpha-toxin and Triacylglycerol lipase) domain and belong to the PLAT-plant-stress protein family are ubiquitously present in monocot and dicots. However, the function of PLAT-plant-stress proteins is still poorly understood. Therefore, we have assessed the function of the uncharacterised Arabidopsis PLAT-plant-stress family members through a combination of functional genetic and physiological approaches. PLAT1 overexpression conferred increased abiotic stress tolerance, including cold, drought and salt stress, while loss-of-function resulted in opposite effects on abiotic stress tolerance. Strikingly, PLAT1 promoted growth under non-stressed conditions. Abiotic stress treatments induced PLAT1 expression and caused expansion of its expression domain. The ABF/ABRE transcription factors, which are positive mediators of abscisic acid signalling, activate PLAT1 promoter activity in transactivation assays and directly bind to the ABRE elements located in this promoter in electrophoretic mobility shift assays. This suggests that PLAT1 represents a novel downstream target of the abscisic acid signalling pathway. Thus, we showed that PLAT1 critically functions as positive regulator of abiotic stress tolerance, but also is involved in regulating plant growth, and thereby assigned a function to this previously uncharacterised PLAT domain protein. The functional data obtained for PLAT1 support that PLAT-plant-stress proteins in general could be promising targets for improving abiotic stress tolerance without yield penalty.
8,5' cyclopurine deoxynucleosides (cPu) are locally distorting DNA base lesions corrected by nucleotide excision repair (NER) and proposed to play a role in neurodegeneration prevalent in genetically defined Xeroderma pigmentosum (XP) patients. In the current study, purified recombinant helicases from different classifications based on sequence homology were examined for their ability to unwind partial duplex DNA substrates harboring a single site-specific cPu adduct. Superfamily (SF) 2 RecQ helicases (RECQ1, BLM, WRN, RecQ) were inhibited by cPu in the helicase translocating strand, whereas helicases from SF1 (UvrD) and SF4 (DnaB) tolerated cPu in either strand. SF2 Fe-S helicases (FANCJ, DDX11 (ChlR1), DinG, XPD) displayed marked differences in their ability to unwind the cPu DNA substrates. Archaeal Thermoplasma acidophilum XPD (taXPD), homologue to the human XPD helicase involved in NER DNA damage verification, was impeded by cPu in the non-translocating strand, while FANCJ was uniquely inhibited by the cPu in the translocating strand. Sequestration experiments demonstrated that FANCJ became trapped by the translocating strand cPu whereas RECQ1 was not, suggesting the two SF2 helicases interact with the cPu lesion by distinct mechanisms despite strand-specific inhibition for both. Using a protein trap to simulate single-turnover conditions, the rate of FANCJ or RECQ1 helicase activity was reduced 10-fold and 4.5-fold, respectively, by cPu in the translocating strand. In contrast, single-turnover rates of DNA unwinding by DDX11 and UvrD helicases were only modestly affected by the cPu lesion in the translocating strand. The marked difference in effect of the translocating strand cPu on rate of DNA unwinding between DDX11 and FANCJ helicase suggests the two Fe-S cluster helicases unwind damaged DNA by distinct mechanisms. The apparent complexity of helicase encounters with an unusual form of oxidative damage is likely to have important consequences in the cellular response to DNA damage and DNA repair.
The paracaspase Malt1 is a central regulator of antigen receptor signaling that is frequently mutated in human lymphoma. As a scaffold, it assembles protein complexes for NF-kappa B activation, and its proteolytic domain cleaves negative NF-kappa B regulators for signal enforcement. Still, the physiological functions of Malt1-protease are unknown. We demonstrate that targeted Malt1-paracaspase inactivation induces a lethal inflammatory syndrome with lymphocyte-dependent neurodegeneration in vivo. Paracaspase activity is essential for regulatory T cell (Treg) and innate-like B cell development, but it is largely dispensable for overcoming Malt1-dependent thresholds for lymphocyte activation. In addition to NF-kappa B inhibitors, Malt1 cleaves an entire set of mRNA stability regulators, including Roquin-1, Roquin-2, and Regnase-1, and paracaspase inactivation results in excessive interferon gamma (IFN gamma) production by effector lymphocytes that drive pathology. Together, our results reveal distinct threshold and modulatory functions of Malt1 that differentially control lymphocyte differentiation and activation pathways and demonstrate that selective paracaspase blockage skews systemic immunity toward destructive autoinflammation.
Die bSSFP-Sequenz kombiniert kurze Akquisitionszeiten mit einem hohen Signal-zu-Rausch-Verhältnis, was sie zu einer vielversprechenden Bildgebungsmethode macht. Im klinischen Alltag ist diese Technik jedoch bisher - abgesehen von vereinzelten Anwendungen - kaum etabliert. Die Hauptgründe hierfür sind Signalauslöschungen in Form von Bandingartefakten sowie der erzielte T2/T1-gewichtete Mischkontrast. Das Ziel dieser Dissertation war die Entwicklung von Methoden zur Lösung der beiden genannten Limitationen, um so eine umfassendere Verwendung von bSSFP für die MR-Diagnostik zu ermöglichen.
Magnetfeldinhomogenitäten, die im Wesentlichen durch Suszeptibilitätsunterschiede oder Imperfektionen seitens der Scannerhardware hervorgerufen werden, äußern sich bei der bSSFP-Bildgebung in Form von Bandingartefakten. Mit DYPR-SSFP (DYnamically Phase-cycled Radial bSSFP) wurde ein Verfahren vorgestellt, um diese Signalauslöschungen effizient zu entfernen. Während für bereits existierende Methoden mehrere separate bSSFP-Bilder akquiriert und anschließend kombiniert werden müssen, ist für die Bandingentfernung mittels DYPR-SSFP lediglich die Aufnahme eines einzelnen Bildes notwendig. Dies wird durch die neuartige Kombination eines dynamischen Phasenzyklus mit einer radialen Trajektorie mit quasizufälligem Abtastschema ermöglicht. Die notwendigen Bestandteile können mit geringem Aufwand implementiert werden. Des Weiteren ist kein spezielles Rekonstruktionsschema notwendig, was die breite Anwendbarkeit des entwickelten Ansatzes ermöglicht. Konventionelle Methoden zur Entfernung von Bandingartefakten werden sowohl bezüglich ihrer Robustheit als auch bezüglich der notwendigen Messzeit übertroffen.
Um die Anwendbarkeit von DYPR-SSFP auch jenseits der gewöhnlichen Bildgebung zu demonstrieren, wurde die Methode mit der Fett-Wasser-Separation kombiniert. Basierend auf der Dixon-Technik konnten so hochaufgelöste Fett- sowie Wasserbilder erzeugt werden. Aufgrund der Bewegungsinsensitivät der zugrunde liegenden radialen Trajektorie konnten die Messungen unter freier Atmung durchgeführt werden, ohne dass nennenswerte Beeinträchtigungen der Bildqualität auftraten. Die erzielten Ergebnisse am Abdomen zeigten weder Fehlzuordnungen von Fett- und Wasserpixeln noch verbleibende Bandingartefakte.
Ein Nachteil der gewöhnlichen Dixon-basierten Fett-Wasser-Separation ist es, dass mehrere separate Bilder zu verschiedenen Echozeiten benötigt werden. Dies führt zu einer entsprechenden Verlängerung der zugehörigen Messzeit. Abhilfe schafft hier die Verwendung einer Multiecho-Sequenz. Wie gezeigt werden konnte, ermöglicht eine derartige Kombination die robuste, bandingfreie Fett-Wasser-Separation in klinisch akzeptablen Messzeiten.
DYPR-SSFP erlaubt die Entfernung von Bandingartefakten selbst bei starken Magnetfeldinhomogenitäten. Dennoch ist es möglich, dass Signalauslöschungen aufgrund des Effekts der Intravoxeldephasierung verbleiben. Dieses Problem tritt primär bei der Bildgebung von Implantaten oder am Ultrahochfeld auf. Als Abhilfe hierfür wurde die Kombination von DYPR-SSFP mit der sogenannten z-Shim-Technik untersucht, was die Entfernung dieser Artefakte auf Kosten einer erhöhten Messzeit ermöglichte.
Die mit DYPR-SSFP akquirierten radialen Projektionen weisen aufgrund des angewendeten dynamischen Phasenzyklus leicht verschiedene Signallevel und Phasen auf. Diese Tatsache zeigt sich durch inkohärente Bildartefakte, die sich jedoch durch eine Erhöhung der Projektionsanzahl effektiv reduzieren lassen. Folglich bietet es sich in diesem Kontext an, Anwendungen zu wählen, bei denen bereits intrinsisch eine verhältnismäßig hohe Anzahl von Projektionen benötigt wird. Hierbei hat sich gezeigt, dass neben der hochaufgelösten Bildgebung die Wahl einer 3D radialen Trajektorie eine aussichtsreiche Kombination darstellt. Die in der vorliegenden Arbeit vorgestellte 3D DYPR-SSFP-Technik erlaubte so die isotrope bandingfreie bSSFP-Bildgebung, wobei die Messzeit im Vergleich zu einer gewöhnlichen bSSFP-Akquisition konstant gehalten werden konnte. Verbleibende, durch den dynamischen Phasenzyklus hervorgerufene Artefakte konnten effektiv mit einem Rauschunterdrückungsalgorithmus reduziert werden. Anhand Probandenmessungen wurde gezeigt, dass 3D DYPR-SSFP einen aussichtsreichen Kandidaten für die Bildgebung von Hirnnerven sowie des Bewegungsapparats darstellt.
Während die DYPR-SSFP-Methode sowie die darauf beruhenden Weiterentwicklungen effiziente Lösungen für das Problem der Bandingartefakte bei der bSSFP-Bildgebung darstellen, adressiert die vorgestellte RA-TOSSI-Technik (RAdial T-One sensitive and insensitive Steady-State Imaging) das Problem des bSSFP-Mischkontrasts. Die Möglichkeit der Generierung von T2-Kontrasten basierend auf der bSSFP-Sequenz konnte bereits in vorausgehenden Arbeiten gezeigt werden. Hierbei wurde die Tatsache ausgenutzt, dass der T1-Anteil des Signalverlaufs nach Beginn einer bSSFP-Akquisition durch das Einfügen von Inversionspulsen in ungleichmäßigen Abständen aufgehoben werden kann. Ein so akquiriertes Bild weist folglich einen reinen, klinisch relevanten T2-Kontrast auf. Die im Rahmen dieser Arbeit vorgestellte Methode basiert auf dem gleichen Prinzip, jedoch wurde anstelle einer gewöhnlichen kartesischen Trajektorie eine radiale Trajektorie in Kombination mit einer KWIC-Filter-Rekonstruktion verwendet. Somit können bei gleichbleibender oder sogar verbesserter Bildqualität aus einem einzelnen, mit RA-TOSSI akquirierten Datensatz verschiedene T2-Wichtungen als auch gewöhnliche T2/T1-Wichtungen generiert werden. Mittels Variation der Anzahl der eingefügten Inversionspulse konnte ferner gezeigt werden, dass es neben den besagten Wichtungen möglich ist, zusätzliche Kontraste zu generieren, bei denen verschiedene Substanzen im Bild ausgelöscht sind. Diese Substanzen können am Beispiel der Gehirnbildgebung Fett, graue Masse, weiße Masse oder CSF umfassen und zeichnen sich neben den reinen T2-Kontrasten durch eine ähnlich hohe klinische Relevanz aus. Die mögliche Bedeutung der vorgestellten Methode für die klinische Verwendung wurde durch Messungen an einer Gehirntumorpatientin demonstriert.
Zusammenfassend lässt sich sagen, dass die im Rahmen dieser Dissertation entwickelten Techniken einen wertvollen Beitrag zur Lösung der eingangs beschriebenen Probleme der bSSFP-Bildgebung darstellen. Mit DYPR-SSFP akquirierte Bilder sind bereits mit bestehender, kommerzieller Rekonstruktionssoftware direkt am Scanner rekonstruierbar. Die Software für die Rekonstruktion von RA-TOSSI-Datensätzen wurde für Siemens Scanner implementiert. Folglich sind beide Methoden für klinische Studien einsetzbar, was gleichzeitig den Ausblick dieser Arbeit darstellt.
Oncolytic viral therapies have shown great promise pre-clinically and in human clinical trials for the treatment of various cancers. Oncolytic viruses selectively infect and replicate in cancer cells, destroying tumor tissue via cell lysis, while leaving noncancerous tissues unharmed. Vaccinia virus (VACV) is arguably one of the safest viruses, which has been intensively studied in molecular biology and pathogenesis as a vaccine for the eradication of smallpox in more than 200 million people. It has fast and efficient replication, and cytoplasmic replication of the virus lessens the chance of recombination or integration of viral DNA into the genome of host cells. Anti-tumor therapeutic efficacy of VACV has been demonstrated for human cancers in xenograft models with a variety of tumor types. In addition recombinant oncolytic VACVs carrying imaging genes represent an advance in treatment strategy that combines tumor-specific therapeutics as well as diagnostics.
As for other targeted therapies, a number of challenges remain for the clinical translation of oncolytic virotherapy. These challenges include the potential safety risk of replication of oncolytic virus in non-tumor tissue, the relatively poor virus spread throughout solid tumor tissue and the disadvantageous ratio between anti-viral and anti-tumoral immunity. However, manipulation of components of the tumor microenvironment may help oncolytic virus infection in killing the tumor tissue and thereby increasing the anti-tumor efficacy. Furthermore, dogs with natural cancer are considered as one of the best animal models to develop new drugs for cancer therapy. Traditionally, rodent cancer models have been used for development of cancer therapeutics. However, they do not adequately represent several features that define cancer in humans, including biology of initiation of tumor, the complexity of cancer recurrence and metastasis and outcomes to novel therapies. However, the tumor microenvironment, histopathology, molecular and genomics data from dog tumors has significant similarities with corresponding human tumors. These advantages of pet dog cancers provide a unique opportunity to integrate canine cancer patients in the studies designed for the development of new cancer drugs targeted against both human and canine cancers. This dissertation centers on the use of VACV strains in canine cancer xenografts with the aim of understanding the effects of modulation of tumor microenvironment on VACV-mediated tumor therapy.
In the first studies, wild-type VACV strain LIVP6.1.1 was tested for its oncolytic efficiency in canine soft tissue sarcoma (STSA-1) and canine prostate carcinoma (DT08/40) cells in culture and xenografts models. LIVP6.1.1 infected, replicated within, and killed both STSA-1 and DT08/40 cells in cell culture. The replication of virus was more efficient in STSA-1 cells compared to DT08/40 cells. In xenograft mouse models, LIVP6.1.1 was safe and effective in regressing both STSA-1 and DT08/40 xenografts. However, tumor regression was faster in STSA-1 xenografts compared to DT08/40 xenografts presumably due to more efficient replication of virus in STSA-1 cells. Biodistribution profiles revealed persistence of virus in tumors 5 and 7 weeks post virus injection in STSA-1 and DT08/40 xenografts, respectively, with the virus mainly cleared from all other major organs. Immunofluorescence staining detected successful colonization of VACV in the tumor. Consequently, LIVP6.1.1 colonization in the tumor showed infiltration of innate immune cells mainly granulocytes and macrophages in STSA-1 tumor xenografts. These findings suggest that virotherapy-mediated anti-tumor mechanism in xenografts could be a combination of direct viral oncolysis of tumor cells and virus-dependent infiltration of tumor-associated host immune cells.
In further studies, the effects of modulation of tumor angiogenesis of VACV therapy were analyzed in canine cancer xenografts. GLV-1h109 VACV strain (derived from prototype virus GLV-1h68) encoding the anti-VEGF single chain antibody GLAF-1 was characterized for its oncolytic efficacy in STSA-1 and DT08/40 cancer cells in culture and tumor xenografts. Concomitantly, the effects of locally expressed GLAF- 1 in tumors on virus replication, host immune infiltration, tumor vascularization and tumor growth were also evaluated.
GLV-1h109 was shown to be similar to the parental virus GLV-1h68 in expression of the two marker genes that both virus strains have in common (Ruc-GFP and gusA) in cell cultures. Additionally, the anti-VEGF single-chain antibody GLAF-1 was expressed by GLV-1h109 in both cell cultures and tumor xenografts. The insertion of GLAF-1 did not significantly affect the replication and cytotoxicity of GLV-1h109 in the STSA-1 and DT08/40 cell lines, although at early time points (24-48 hpi), the replication of GLV-1h109 was higher in STSA-1 cells compared to DT08/40 cells. In addition, STSA-1 cells were more susceptible to lysis with GLV-1h109 than DT08/40 cells. GLV-1h109 achieved a significant inhibition of tumor growth in both STSA-1 and DT08/40 canine xenografts models. Consequently, the significant regression of tumor growth was initiated earlier in STSA-1 tumor xenografts compared to regression in DT08/40 xenografts. The reason for the higher efficacy of GLV-1h109 in STSA-1 xenografts than DT08/40 xenografts was attributed to more efficient replication of virus in STSA-1 cells. In addition, tumor-specific virus infection led to a continued presence of GLAF-1 in peripheral blood, which could be useful as a pharmacokinetic marker to monitor virus colonization and persistence in GLV-1h109- injected xenograft mice. GLAF-1 is a single-chain antibody targeting human and murine VEGF. It was demonstrated that GLAF-1 was functional and recognized both canine and human VEGF with equal efficiency.
Histological analysis of tumor sections 7 days after GLV-1h109 injection confirmed that colonization of VACV and intratumoral expression of GLAF-1 translated into a significant decrease in blood vessel number compared to GLV-1h68 or PBS-treated control tumors. Subsequently, reduction in blood vessel density significantly improved the spread and replication of VACV as observed by FACS analysis and standard plaque assay, respectively. Inhibition of tumor angiogenesis and increased replication of virus further improved the infiltration of innate immune cells mainly granulocytes and macrophages in STSA-1 tumor xenografts. Both the results, i.e. improved virus spread and increased infiltration of innate immune cells in tumor, were explained by a phenomenon called “vascular normalization”, where anti-VEGF therapy normalizes the heterogeneous tumor vasculature thereby improving delivery and spread of VACV. In summary, the effects of inhibition of tumor angiogenesis on virus spread and replication were demonstrated using a vaccinia virus caring an anti- angiogenic payload targeting vascular endothelial growth factor (VEGF) in canine cancer xenografts.
In the final studies, the effects of VACV therapy on modulation of the immune system were analyzed in canine cancer patients enrolled in a phase I clinical trial. V-VET1 (clinical grade LIVP6.1.1 VACV) injection significantly increased the percentages of CD3+CD8+ T lymphocytes at 21 days after initiation of treatment. CD3+CD8+ T lymphocytes are mainly cytotoxic T lymphocytes that have potential to lyse cancer cells. Subsequently, the frequency of immune suppressor cells, mainly MDSCs and Treg was also analyzed in peripheral blood of canine cancer patients. Increase in the MDSC population and decreased CD8/Treg ratio is known to have inhibitory effects on the functions of cytotoxic T cells. We demonstrated that injection of V-VET1 in canine cancer patients significantly reduced the percentages of MDSCs at 21 days post initiation of treatment. Additionally, CD8/Treg ratio was increased 21 days after initiation of V-VET1 treatment. We also showed that changes in the frequency of immune cells neither depends on dose of virus nor depends on tumor type according to the data observed from this clinical trial with eleven analyzed patients.
This preclinical and clinical data have important clinical implications of how VACV therapy can be used for the treatment of canine cancers. Moreover, dogs with natural cancers can be used as an ideal animal model to improve the oncolytic virotherapy for human cancers. Furthermore, modulation of tumor microenvironment mainly tumor angiogenesis and tumor immunity has significant impact on the success of oncolytic virotherapy.
Besides HIV and tuberculosis, malaria still is one of the most devastating infectious diseases especially in developing countries, with Plasmodium falciparum being responsible for the frequently lethal form of malaria tropica. It is a major cause of mortality as well as morbidity, whereby pregnant women and children under the age of five years are most severely affected. Rapidly emerging drug resistances and the lack of an effective and safe vaccine hamper the combat against malaria by chemical and pharmacological regimens, and moreover the poor socio-economic and healthcare conditions in malaria-endemic countries are compromising the extermination of this deadly tropical disease to a large extent. Malaria research is still questing for druggable targets in the parasitic protozoan which pledge to be refractory against evolving resistance-mediating mutations and yet constitute affordable and compliant antimalarial chemotherapeutics.
The parasite kinome consists of members that represent most eukaryotic protein kinase groups, but also contains several groups that can not be assigned to conservative ePK groups. Moreover, given the remarkable divergence of plasmodial kinases in respect to the human host kinome and the fact that several plasmodial kinases have been identified that are essential for the intraerythrocytic developmental cycle, these parasite enzymes represent auspicious targets for antimalarial regimens. Despite elaborate investigations on several other ePK groups, merely scant research has been conducted regarding the four identified members of the cyclin-dependent kinase-like kinase (CLK) family, PfCLK-1-4. In other eukaryotes, CLKs are involved in mRNA processing and splicing by means of phosphorylation of serine/arginine-rich (SR) proteins, which are crucial components of the splicing machinery in the alternative splicing pathway. All four PfCLKs are abundantly expressed in asexual parasites and gametocytes, and stage-specific expression profiles of PfCLK-1 and PfCLK-2 exhibited nucleus-associated localization and an association with phosphorylation activity. In the course of this study, PfCLK-3 and PfCLK-4 were functionally characterized by indirect immunofluorescence, Western blot analysis and kinase activity assays. These data confirm that the two kinases are primarily expressed in the nucleus of trophozoites and both kinases possess in vitro phosphorylation activity on physiological substrates. Likewise PfCLK-1 and PfCLK-2, reverse genetic studies exhibited the indispensability of both PfCLKs on the asexual life cycle of P. falciparum, rendering them as potential candidates for antiplasmodial strategies. Moreover, this study was conducted to identify putative SR proteins as substrates of all four PfCLKs. Previous alignments revealed a significant homology of the parasite CLKs to yeast SR protein kinase Sky1p. Kinase activity assays showed in vitro phosphorylation of the yeast Sky1p substrate and SR protein Npl3p by precipitated PfCLKs. In addition, four homologous plasmodial SR proteins were identified that are phosphorylated by PfCLKs in vitro: PfASF-1, PFSRSF12, PfSFRS4 and PfSR-1. All four parasite SR splicing factors are predominantly expressed in the nuclei of trophozoites. For PfCLK-1, a co-localization with the SR proteins was verified.
Finally, a library of human and microbial CLK inhibitors and the antiseptic chlorhexidine (CHX) was screened to determine their inhibitory effect on different parasite life cycle stages and on the PfCLKs specifically. Five inhibitors out of 63 compounds from the investigated library were selected that show a moderate inhibition on asexual life cycle stages with IC50 values ranging between approximately 4 and 8 µM. Noteworthy, these inhibitors belong to the substance classes of aminopyrimidines or oxo-β-carbolines. Actually, the antibiotic compound CHX demonstrated an IC50 in the low nanomolar range. Stage-of-inhibition assays revealed that CHX severely affects the formation of schizonts. All of the selected CLKs inhibitors also affect gametocytogenesis as well as gametogenesis, as scrutinized in gametocyte toxicity assays and exflagellation assays, respectively. Kinase activity assays confirm a specific inhibition of CLK-mediated phosphorylation of all four kinases, when the CLK inhibitors are applied on immunoprecipitated PfCLKs. These findings on PfCLK-inhibiting compounds are initial attempts to determine putative antimalarial compounds targeting the PfCLKs. Moreover, these results provide an effective means to generate chemical kinase KOs in order to phenotypically study the role of the PfCLKs especially in splicing events and mRNA metabolism. This approach of functionally characterizing the CLKs in P. falciparum is of particular interest since the malarial spliceosome is still poorly understood and will gain further insight into the parasite splicing machinery.
The general map-labeling problem is as follows: given a set of geometric objects to be labeled, or features, in the plane, and for each feature a set of label positions, maximize the number of placed labels such that there is at most one label per feature and no two labels overlap. There are three types of features in a map: point, line, and area features. Unfortunately, one cannot expect to find efficient algorithms that solve the labeling problem optimally.
Interactive maps are digital maps that only show a small part of the entire map whereas the user can manipulate the shown part, the view, by continuously panning, zooming, rotating, and tilting (that is, changing the perspective between a top and a bird view). An example for the application of interactive maps is in navigational devices. Interactive maps are challenging in that the labeling must be updated whenever labels leave the view and, while zooming, the label size must be constant on the screen (which either makes space for further labels or makes labels overlap when zooming in or out, respectively). These updates must be computed in real time, that is, the computation must be so fast that the user does not notice that we spend time on the computation. Additionally, labels must not jump or flicker, that is, labels must not suddenly change their positions or, while zooming out, a vanished label must not appear again.
In this thesis, we present efficient algorithms that dynamically label point and line features in interactive maps. We try to label as many features as possible while we prohibit labels that overlap, jump, and flicker. We have implemented all our approaches and tested them on real-world data. We conclude that our algorithms are indeed real-time capable.